In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...

Extended survival times and inhibited growth of patient-derived glioblastoma brain tumours have been achieved in mice with CRISPR-Cas9 mediated...

Caribou Biosciences recently shared positive clinical data for its CRISPR-edited CAR-T cell therapy, CB-010, in patients with relapsed/refractory B...

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

Resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer. By profiling the spectrum of outcomes arising from...

Researchers at Ulsan National Institute of Science and Technology in South Korea have developed a CRISPR-Cas9-based method to eliminate tumour cells....

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...